Clinical application of natural killer (NK) cells against leukemia is an area of intense investigation. In human leukocyte antigen-mismatched allogeneic hematopoietic stem cell transplantations (HSCT), alloreactive NK cells exert powerful anti-leukemic activity in preventing relapse in the absence of graft-versus-host disease, particularly in acute myeloid leukemia patients. Adoptive transfer of donor NK cells post-HSCT or in non-transplant scenarios may be superior to the currently widely used unmanipulated donor lymphocyte infusion. This concept could be further improved through transfusion of activated NK cells. Significant progress has been made in good manufacturing practice (GMP)-compliant large-scale production of stimulated effectors. However, inherent limitations remain. These include differing yields and compositions of the end-product due to donor variability and inefficient means for cryopreservation. Moreover, the impact of the various novel activation strategies on NK cell biology and in vivo behavior are barely understood. In contrast, reproduction of the thirdparty NK-92 drug from a cryostored GMP-compliant master cell bank is straightforward and efficient. Safety for the application of this highly cytotoxic cell line was demonstrated in first clinical trials. This novel ‘off-theshelf’ product could become a treatment option for a broad patient population. For specific tumor targeting chimeric-antigen-receptor-engineered NK-92 cells have been designed.

Die vorliegende Arbeit beinhaltet die Generierung und Evaluation von Natürlichen Killerzellen, die EGFRvIII-positive und SDF-1alpha sekretierende primäre Glioblastomzellen aufspüren, erkennen und effizient abtöten können. Die Kombination der gelenkten Zytotoxizität mit einer optimierten Migration von Effektorzellen des Immunsystems wird auf Grundlage der in dieser Arbeit gewonnenen Daten als ein vielversprechender Ansatz für eine zukünftige Therapie des primären Glioblastoms vorgeschlagen.

Human cytomegalovirus (HCMV, Herpesviridae) can cause severe complications in the infected individuals undergoing hematopoietic stem cell transplantation. Nowadays, these patients are treated using antivirotics or HCMV-specific T cells derived from the seropositive graft donor. This study explored the possibility of redirecting HCMV-non-specific T cells from a seronegative donor towards HCMV-infected cells via chimeric antigen receptor (CAR), i.e. artificially designed T cell receptor. Viral glycoprotein B (gB) has been selected as a target for this receptor. Published sequence of a single chain variable fragment of a human antibody was used for the design of the CAR against gB (gBCAR). After the verification of production and surface localization in cell lines, gBCAR was being introduced into human T cells via lentiviral vectors. Human fetal lung fibroblasts (LEP) infected with HCMV were used as target cells after the expression of gB at their surface was demonstrated. gBCAR functionality was evaluated by the incubation of modified T cells with infected cells and subsequent analysis of media for IFNγ concentration, which was significantly higher in the setting of gBCAR T cells incubated with HCMV-LEP than in the control incubations. The results obtained show the specificity of gBCAR against...

Background: The CD19 chimeric antigen receptor (CAR) adoptive T-cell therapy for B-cell leukemia is a promising treatment for relapsed or refractory malignities. The overall response rate of CD19 CAR-T cells in clinical trials was greater than 80% for patients with B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin's lymphoma (NHL). However, CAR-T cell therapy of leukemias and solid tumors has been limited by a lot of factors such as antigen loss of tumor escape variants, reduced proliferation, persistence and tumor-infiltration of CAR-T cells in vivo, immunosuppressive tumor environment, absence of ideal antigens and on-target, off-tumor toxicities. Therefore, new strategies improving the safety and efficacy of CAR-T cells, including further T-cell modification to overcome the immune suppression, are tested. Aims: (i) Bispecific CARs designed to express two antigen-binding domains prevent of antigen escape. (ii) T-cells were genetically modified to express CAR along with an inducible IL-21 gene cassette driven by NFAT-responsive promoter. IL-21 directly enhances CAR-T cell activity and anti-tumor effects. (iii) Applying suicide epitope modification in CAR enables significantly increasing the therapeutic safety of CAR-T cells. Methods: CARs were constructed by using molecular biology...

Cancer immunotherapies utilize the capabilities of the immune system to efficiently target malignant cells. In recent years, chimeric antigen receptor (CAR) equipped T cells showed promising results against B cell lymphomas. Autologous CAR-T cells require patientspecific manufacturing and thus extensive production facilities, resulting in high priced therapies. Along with potentially severe side effects, these are the major drawbacks of CAR-T cells therapies. Natural Killer (NK) cells pose an alternative for CAR equipped immune cells. Since NK cells can be safely transferred from healthy donors to cancer patients, they present a suitable platform for an allogeneic “off-the-shelf” immunotherapy. However, administration of activated NK cells in cancer therapy has until now shown poor anti-cancer responses, especially in solid tumors. Genetic modifications such as CARs promise to enhance recognition of tumor cells, thereby increasing anti-tumor effects and improving clinical efficacy. Although the cell biology of T and NK cells deviates in many aspects, the development of CAR-NK cells frequently follows within the footsteps of CART cells, meaning that T cell technologies are simply adopted to NK cells. In this review, we underline the unique properties of NK cells and their potential in CAR therapies. First, we summarize the characteristics of NK cell biology with a focus on signaling, a fine-tuned interaction of activating and inhibitory receptors. We then discuss why tailored NK cellspecific CAR designs promise superior efficacy compared to designs developed for T cells. We summarize current findings and developments in the CAR-NK landscape: different CAR formats and modifications to optimize signaling, to target a broader pool of antigens or to increase in vivo persistence. Finally, we address challenges beyond NK cell engineering, including expansion and manufacturing, that need to be addressed to pave the way for CAR-NK therapies from the bench to the clinics.

Background: With increasing clinical use of NK-92 cells and their CAR-modified derivatives in cancer immunotherapy, there is a growing demand for efficient production processes of these “off-the-shelf” therapeutics. In order to ensure safety and prevent the occurrence of secondary tumors, (CAR-)NK-92 cell proliferation has to be inactivated before transfusion. This is commonly achieved by gamma irradiation. Recently, we showed proof of concept that low energy electron irradiation (LEEI) is a new method for NK-92 inactivation. LEEI has several advantages over gamma irradiation, including a faster reaction time, a more reproducible dose rate and much less requirements on radiation shielding. Here, LEEI was further evaluated as a promising alternative to gamma irradiation yielding cells with highly maintained cytotoxic effector function. Methods: Effectiveness and efficiency of LEEI and gamma irradiation were analyzed using NK-92 and CD123-directed CAR-NK-92 cells. LEE-irradiated cells were extensively characterized and compared to gamma-irradiated cells via flow cytometry, cytotoxicity assays, and comet assays, amongst others. Results: Our results show that both irradiation methods caused a progressive decrease in cell viability and are, therefore, suitable for inhibition of cell proliferation. Notably, the NKmediated specific lysis of tumor cells was maintained at stable levels for three days postirradiation, with a trend towards higher activities after LEEI treatment as compared to gamma irradiation. Both gamma irradiation as well as LEEI led to substantial DNA damage and an accumulation of irradiated cells in the G2/M cell cycle phases. In addition, transcriptomic analysis of irradiated cells revealed approximately 12-fold more differentially expressed genes two hours after gamma irradiation, compared to LEEI. Analysis of surface molecules revealed an irradiation-induced decrease in surface expression of CD56, but no changes in the levels of the activating receptors NKp46, NKG2D, or NKp30. Conclusions: The presented data show that LEEI inactivates (CAR-)NK-92 cells as efficiently as gamma irradiation, but with less impact on the overall gene expression. Due to logistic advantages, LEEI might provide a superior alternative for the manufacture of (CAR-)NK-92 cells for clinical application.

No description available.

Introdução: A Síndrome de Down (SD) é uma doença genética de alta prevalência, com várias alterações imunológicas decorrentes da disfunção tímica associada à doença. Neste estudo, avaliou-se a associação entre presença de autoimunidade e disfunção do timo em pacientes com SD. Métodos: Foram avaliados 22 pacientes com SD (11 com autoimunidade e 11 sem), que preenchiam os critérios de inclusão: diagnóstico clinico e genético, idade > a 10 anos e sem uso de drogas imunossupressoras. Estes pacientes foram comparados a um grupo controle formado por adolescentes saudáveis (n=11) e outro de pacientes com doenças autoimunes, caracterizados por manifestações clínicas e presença de autoanticorpos (n=11). Todos os grupos foram pareados por idade e sexo. Os parâmetros laboratoriais avaliados foram: número de leucócitos, linfócitos CD3+, CD4+, CD8+, CD19+, CD21+, CD4+CD28null , células T reguladoras (CD4+CD25+Foxp3+), linfócitos T naive (CD4+CD45RA+CD62L+) e linfócitos T de memória (CD4+CD45RO+CD62L- ) e célula NK (CD3-CD16+, CD56+) por citometria de fluxo, Foi também avaliada a concentração de sjTREC (T receptor excision circles) em sangue total por qRT-PCR .Resultados: Nos pacientes com SD, observou-se redução das concentrações séricas de sjTREC, do número de linfócitos B e aumento do número de células CD4+CD28null. Na análise concomitante entre os grupos formados (SD com e sem autoimunidade, controle e autoimunidade sem SD), após correção de Bonferroni, observou-se que o grupo SD com autoimunidade apresentou redução de linfócitos T CD4, linfócitos naive e linfócitos B. Quando comparados os grupos SD com e sem autoimunidade observou-se redução significativa das concentrações de TREC no primeiro grupo. Não houve alterações das Células NK. Em valores percentuais, os pacientes com SD e autoimunidade apresentaram elevação da subpopulação de células T reguladoras. Conclusões: Este estudo mostra que pacientes com SD apresentam disfunção tímica quando avaliados pela quantificação de concentrações de TREC, sendo esta última mais expressiva nos pacientes com SD e autoimunidade. A redução dos linfócitos T naive associada a número normal de linfócitos T de memória sugere disfunção tímica primária, não compatível com processo de senescência. A observação do aumento do número de linfócitos CD4+CD28null poderia ser consequência de múltiplos estímulos celulares provavelmente em consequência da linfopenia observada. A elevação de células Treg em pacientes com SD e autoimunidade poderia ser decorrente de alterações funcionais destas células bem como de alterações nos processos de homeostase / Introduction: Down syndrome (DS) is a genetic disease of high prevalence, with many immunological alterations as a consequence of thymic disfunction associated to this disease. In this study, it was evaluated the association between the presence of thymic disfunction and autoimmunity in patients with DS. Methods: It was evaluated 22 patients with DS (11 with and 11 without autoimmunity) who fulfilled the inclusion criteria: clinical and genetic diagnosis, and age >10 years and no use of immunosuppressive drugs. These patients were compared to a control group composed by health adolescents (n=11) and patients with autoimmune diseases, characterized by clinical manifestations and autoantibodies (n=11). All groups were matched for age and sex. The laboratory parameters evaluated were: number of leukocytes, CD3+, CD4+, CD8+, CD19+, CD4+CD28null lymphocytes, regulatory T cells (CD4+CD25+Foxp3+), naive T lymphocytes (CD4+CD45RA+CD62L+), memory T lymphocytes (CD4+CD45RO+CD62L-) and NK cells (CD3-CD16+CD56+). The subpopulations of lymphocytes were determined by flow cytometry. It was also evaluated whole blood sjTREC (T receptor excision circles) concentrations by PCR. Results: In DS patients, there was reduction of sjTREC concentration, B lymphocytes number and increase of CD4+CD28null cells number. When compared all the groups formed (SD with and without autoimmunity, autoimmunity without SD and control group), after Bonferroni correction, the SD group with autoimmunity showed a reduction of T CD4+lymphocytes, naïve cells and B lymphocytes. When SD with and without autoimmunity groups were compared it was observed significant reduction in the TREC concentrations in the first group. There were no changes in NK cells. Patients with DS and autoimmune diseases had huge percentages of T reg cells comparing different groups. Conclusions: This study showed that DS patients presented thymic disfunction by reduced levels of whole blood sjTREC, and this condition is more expressive to patients with DS and autoimmune disease associated. The reduction of TCD4+ naïve cells with normal TCD4+ memory cells is suggestive of primary thymic disfunction against a senescent process. The elevated number of CD4+CD28null in DS patients probably was a consequence of reduced T cell numbers. The elevation of Treg cells remains unclear, and coud be a result of ineffective cells or deregulation of Thymus dependent immunity

Introdução: A Síndrome de Down (SD) é uma doença genética de alta prevalência, com várias alterações imunológicas decorrentes da disfunção tímica associada à doença. Neste estudo, avaliou-se a associação entre presença de autoimunidade e disfunção do timo em pacientes com SD. Métodos: Foram avaliados 22 pacientes com SD (11 com autoimunidade e 11 sem), que preenchiam os critérios de inclusão: diagnóstico clinico e genético, idade > a 10 anos e sem uso de drogas imunossupressoras. Estes pacientes foram comparados a um grupo controle formado por adolescentes saudáveis (n=11) e outro de pacientes com doenças autoimunes, caracterizados por manifestações clínicas e presença de autoanticorpos (n=11). Todos os grupos foram pareados por idade e sexo. Os parâmetros laboratoriais avaliados foram: número de leucócitos, linfócitos CD3+, CD4+, CD8+, CD19+, CD21+, CD4+CD28null , células T reguladoras (CD4+CD25+Foxp3+), linfócitos T naive (CD4+CD45RA+CD62L+) e linfócitos T de memória (CD4+CD45RO+CD62L- ) e célula NK (CD3-CD16+, CD56+) por citometria de fluxo, Foi também avaliada a concentração de sjTREC (T receptor excision circles) em sangue total por qRT-PCR .Resultados: Nos pacientes com SD, observou-se redução das concentrações séricas de sjTREC, do número de linfócitos B e aumento do número de células CD4+CD28null. Na análise concomitante entre os grupos formados (SD com e sem autoimunidade, controle e autoimunidade sem SD), após correção de Bonferroni, observou-se que o grupo SD com autoimunidade apresentou redução de linfócitos T CD4, linfócitos naive e linfócitos B. Quando comparados os grupos SD com e sem autoimunidade observou-se redução significativa das concentrações de TREC no primeiro grupo. Não houve alterações das Células NK. Em valores percentuais, os pacientes com SD e autoimunidade apresentaram elevação da subpopulação de células T reguladoras. Conclusões: Este estudo mostra que pacientes com SD apresentam disfunção tímica quando avaliados pela quantificação de concentrações de TREC, sendo esta última mais expressiva nos pacientes com SD e autoimunidade. A redução dos linfócitos T naive associada a número normal de linfócitos T de memória sugere disfunção tímica primária, não compatível com processo de senescência. A observação do aumento do número de linfócitos CD4+CD28null poderia ser consequência de múltiplos estímulos celulares provavelmente em consequência da linfopenia observada. A elevação de células Treg em pacientes com SD e autoimunidade poderia ser decorrente de alterações funcionais destas células bem como de alterações nos processos de homeostase / Introduction: Down syndrome (DS) is a genetic disease of high prevalence, with many immunological alterations as a consequence of thymic disfunction associated to this disease. In this study, it was evaluated the association between the presence of thymic disfunction and autoimmunity in patients with DS. Methods: It was evaluated 22 patients with DS (11 with and 11 without autoimmunity) who fulfilled the inclusion criteria: clinical and genetic diagnosis, and age >10 years and no use of immunosuppressive drugs. These patients were compared to a control group composed by health adolescents (n=11) and patients with autoimmune diseases, characterized by clinical manifestations and autoantibodies (n=11). All groups were matched for age and sex. The laboratory parameters evaluated were: number of leukocytes, CD3+, CD4+, CD8+, CD19+, CD4+CD28null lymphocytes, regulatory T cells (CD4+CD25+Foxp3+), naive T lymphocytes (CD4+CD45RA+CD62L+), memory T lymphocytes (CD4+CD45RO+CD62L-) and NK cells (CD3-CD16+CD56+). The subpopulations of lymphocytes were determined by flow cytometry. It was also evaluated whole blood sjTREC (T receptor excision circles) concentrations by PCR. Results: In DS patients, there was reduction of sjTREC concentration, B lymphocytes number and increase of CD4+CD28null cells number. When compared all the groups formed (SD with and without autoimmunity, autoimmunity without SD and control group), after Bonferroni correction, the SD group with autoimmunity showed a reduction of T CD4+lymphocytes, naïve cells and B lymphocytes. When SD with and without autoimmunity groups were compared it was observed significant reduction in the TREC concentrations in the first group. There were no changes in NK cells. Patients with DS and autoimmune diseases had huge percentages of T reg cells comparing different groups. Conclusions: This study showed that DS patients presented thymic disfunction by reduced levels of whole blood sjTREC, and this condition is more expressive to patients with DS and autoimmune disease associated. The reduction of TCD4+ naïve cells with normal TCD4+ memory cells is suggestive of primary thymic disfunction against a senescent process. The elevated number of CD4+CD28null in DS patients probably was a consequence of reduced T cell numbers. The elevation of Treg cells remains unclear, and coud be a result of ineffective cells or deregulation of Thymus dependent immunity

Helper T cells direct the immunological response to foreign pathogens and cancer. To become activated, helper T cells must recognize unique peptides presented on major histocompatibility complex II (pMHCII) by antigen presenting cells (APCs) with their T cell receptor (TCR). While much is known about helper T cell activation signaling cascades and the subsequent roles of helper T cell subsets, the initiation of helper T cell activation by the TCR and other co-receptors is less well understood. Specifically, the affinity of the TCR for its pMHCII can change helper T cell subset fate, proliferation, and alter the risk for activation induced cell death. High affinity TCRs are attractive targets for immunotherapies, but little is known about how helper T cells respond to high affinity TCRs. Here we describe high affinity TCR activation thresholds for both full length TCRs and chimeric antigen receptor TCRs both with and without the presence of the coreceptor CD4 and propose a mechanism whereby CD4 inhibits T cell activation via Lck sequestration and a CD4-independent method. Dysregulated helper T cells play critical roles in the development and perpetuation of systemic lupus erythematosus (SLE), a systemic autoimmune disease that causes widespread inflammation and organ damage throughout the body. Chronic inflammation in SLE affects the immune response to viruses and the risk of developing cancer. However, in SLE patients, it is unclear if viruses initiate the development of cancer directly or if the effects are non-interacting and concomitant. Here we describe the interactions between SLE, viruses, and cancer risk revealing that viruses and SLE do interact to increase the both the overall cancer risk and the risk for hematological malignancies. Due to vaccine efficacy, vaccine preventable diseases (VPDs) are no longer commonly experienced or understood by the public. Vaccines are a victim of their own success and according to the World Health Organization (WHO), vaccine hesitancy (VH) is one of the top threats to global health. VH is the refusal to accept vaccinations and the reasons for VH vary across time, place, and vaccine. Refuting VH is difficult as directly confronting false assumptions can cause individuals to become more entrenched in their position resulting in confirmation bias. Adults with VH attitudes are often motivated by concerns over personal liberty, harm, independence, and body purity. Here we describe the results of a VPD interview- and education-based intervention geared towards promoting positive vaccine attitudes for young adults and demonstrate that education focused on VPDs is more effective than vaccine safety.